We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 75 of 309 for:    hepatitis b | Recruiting, Not yet recruiting, Available Studies

Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues (HBV)

This study is currently recruiting participants.
Verified June 2016 by IlDong Pharmaceutical Co Ltd
Sponsor:
ClinicalTrials.gov Identifier:
NCT02792088
First Posted: June 7, 2016
Last Update Posted: June 8, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
IlDong Pharmaceutical Co Ltd
  Purpose
To prove that a study drug is noninferior to a control drug with a proportion of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week after 48-week administration of Besifovir 150 mg, or Tenofovir 300 mg as a control drug to chronic hepatitis B patients

Condition Intervention Phase
Chronic Hepatitis B Drug: Besifovir 150mg Drug: Tenofovir 300mg Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

Resource links provided by NLM:


Further study details as provided by IlDong Pharmaceutical Co Ltd:

Primary Outcome Measures:
  • The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week [ Time Frame: at the 48th week ]

Secondary Outcome Measures:
  • The rate of subjects who showed ALT normalized at the 48th week [ Time Frame: at the 48th week ]

Estimated Enrollment: 244
Study Start Date: July 2015
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Besifovir
Besifovir 150 mg q.d.
Drug: Besifovir 150mg
Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Other Name: Besifovir
Active Comparator: Tenofovir
Tenofovir 300 mg q.d.
Drug: Tenofovir 300mg
Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Other Name: Tenofovir

Detailed Description:
  • Screening Period Subject registration is conducted with confirming selection and exclusion criteria after a written consent form is obtained within 42 days before clinical trial drug administration.
  • Baseline Subjects who visit on the date of starting clinical trial drug administration are randomized to a test group or a control group at a ratio of 1:1. Double blindness is applied for both groups.
  • Treatment period Subjects are orally administered with a clinical trial drug q.ds.i.d. for 48 weeks and visit at the 0, 4th, 12th, 24th, 36th, and 48th week for an HBV DNA test, laboratory tests, a physical test, vital signs, and adverse events.
  • Follow-up period Subjects are provided with appropriate treatment after completing the 48-week trial or dropping out. Subjects visit once at the 60th week for follow-up of adverse events, such as acute deterioration of hepatitis B, and HBV DNA test results. If any treatment is not conducted after 48-week administration, subjects visit at intervals of four weeks until a follow-up visit (60th week) and the same tests with the 24th week visit (Visit 5) are conducted. However, subjects who participate in a 48-week separate extended trial conducted after 48-week administration in this clinical trial do not have a follow-up period.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who show positive HBsAg or has a history of chronic hepatitis B for the last six months or more before screening
  • Patients who showed positive HBsAg during screening
  • Have developed nucleoside analogue resistant HB
  • Had no received nucleotide analogue

Exclusion Criteria:

  • Was co-infected with hepatitis C of hepatitis D virus or Human Immunodeficiency Virus
  • Had confirmation of adefovir drug resistant mutation
  • At screening, had alpha-fetoprotein (AFP) value > 20 ng/mL and a follow-up ultrasonography performed prior to baseline showed findings indicative of HCC
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02792088


Contacts
Contact: Junghee Won, Master 82-2-526-3512 jh-won@ildong.com
Contact: Yoan Park, Master 82-2-526-3524 yapark@ildong.com

Locations
Korea, Republic of
Severance Hospital of Yonsei University Recruiting
Seoul, Korea, Republic of
Contact: Kwang-Hyub Han, M.D., Ph.D.         
Principal Investigator: Kwang-Hyub Han, M.D., Ph.D.         
Sponsors and Collaborators
IlDong Pharmaceutical Co Ltd
Investigators
Principal Investigator: Kwang-Hyub Han, M.D, Ph.D. Severance Hospital of Yonsei University
  More Information

Responsible Party: IlDong Pharmaceutical Co Ltd
ClinicalTrials.gov Identifier: NCT02792088     History of Changes
Other Study ID Numbers: ID_BVCL012
First Submitted: May 31, 2016
First Posted: June 7, 2016
Last Update Posted: June 8, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by IlDong Pharmaceutical Co Ltd:
HBV

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Tenofovir
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents